This article has an accompanying continuing medical education activity, also eligible for MOC credit, on page e168. Learning Objective-Upon completion of this activity, successful learners will be able to evaluate the safety profiles of non-vitamin K antagonist oral anticoagulants and interpret the available data regarding their associated risk of gastrointestinal bleeding.
BACKGROUND & AIMS:
Non-vitamin K antagonist oral anticoagulants (NOACs) are convenient and effective in the prevention and treatment of venous thromboembolism and the prevention of stroke in patients with atrial fibrillation. However, these drugs have been associated with an increased risk of gastrointestinal (GI) bleeding. We conducted a systematic review and meta-analysis to determine the risk of GI bleeding in patients receiving these drugs.
METHODS:
We searched the EMBASE, Medline, Cochrane, and ISI Web of knowledge databases through January 2016 for randomized trials that compared NOACs with conventional anticoagulants for approved indications. We conducted a meta-analysis, reporting odds ratios (ORs) with 95% confidence intervals (CIs). The primary outcome was major GI bleeding. Secondary outcomes included clinically relevant nonmajor bleeding and upper and lower GI bleeding. We performed a priori subgroup analyses by individual drug.
RESULTS:
Our analysis included a total of 43 randomized trials, comprising 166,289 patients. There was no difference between NOACs and conventional anticoagulants in the risk of major bleeding (1.5% vs 1.3%, respectively; OR, 0.98; 95% CI, 0.80-1.21), clinically relevant nonmajor bleeding (0.6% vs 0.6%, respectively; OR, 0.93; 95% CI, 0.64-1.36), upper GI bleeding (1.5% vs 1.6%, respectively; OR, 0.96; 95% CI, 0.77-1.20), or lower GI bleeding (1.0% vs 1.0%, respectively; OR, 0.88; 95% CI, 0.67-1.15). Dabigatran (2.0% vs 1.4%, respectively; OR, 1.27; 95% CI, 1.04-1.55) and rivaroxaban (1.7% vs 1.3%, respectively; OR, 1.40; 95% CI, 1.15-1.70) were associated with increased odds of major GI bleeding compared with conventional anticoagulation, whereas no difference was found for apixaban (0.6% vs 0.7%, respectively; OR, 0.81; 95% CI, 0.64-1.02) or edoxaban (1.9% vs 1.6%, respectively; OR, 0.93; 95% CI, 0.78-1.11). These subgroup findings were not observed in other sensitivity analyses.
CONCLUSIONS:
In a systematic review and meta-analysis, we found risk of major GI bleeding to be similar between NOACs and conventional anticoagulation. Dabigatran and rivaroxaban, however, may be associated with increased odds of major GI bleeding. Further high-quality studies are needed to characterize GI bleeding risk among NOACs.
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See editorial on page 1665. N on-vitamin K antagonist oral anticoagulants (NOACs), including direct thrombin and factor Xa inhibitors, have been developed for the prevention and treatment of venous thromboembolism (VTE) and the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF). 1 Several of these agents are licensed for clinical use, having shown noninferior or superior efficacy compared with conventional anticoagulation therapy. 2 Their oral availability and lack of required routine monitoring make them attractive alternatives to heparins and vitamin K antagonists such as warfarin.
Gastrointestinal (GI) bleeding is a particular concern when it comes to anticoagulation therapy. Vitamin K antagonists have been associated with a more than 3-fold increase in odds of GI bleeding compared with placebo or control in a meta-analysis of 2200 patients. 3 In most of the large AF trials, NOACs were associated with a higher risk of GI bleeding compared with warfarin, with apixaban being the notable exception. 4, 5 Data on GI bleeding risk in the context of VTE prophylaxis and treatment are limited because of the low reported rates of major bleeding in general. 2 With the exception of dabigatran, NOACs have no approved reversal agent at this time, making the question of GI bleeding risk even more consequential. We therefore conducted a systematic review and metaanalysis to determine the risk of GI bleeding associated with available NOACs as compared with conventional anticoagulation therapy.
Methods

Search Strategy
Systematic searches were performed using MEDLINE, EMBASE, Cochrane, and ISI Web of knowledge from January 1980 through January 2016. A highly sensitive search strategy was used to identify reports of randomized controlled trials (RCTs) with a combination of Medical Subject Heading terms and text words related to GI bleeding and NOACs (Supplementary Methods). Recursive searches, cross-referencing, and hand searches were performed.
Trial Selection and Patient Population
All RCTs were included, both fully published and those in abstract form, that compared NOACs with conventional anticoagulation therapy for the prevention or treatment of VTE, or for the prevention of stroke and systemic embolism in patients with AF. Trials comparing NOACs with placebo or aspirin also were considered. Trials were excluded for the following reasons: inclusion of nonhuman subjects, pharmacodynamic or dose-ranging studies, non-English or French publications, or failure to include bleeding as a specified outcome. Trials assessing NOACs for the treatment of acute coronary syndrome or other unapproved indications also were excluded. The eligibility of studies was assessed independently by 2 investigators (C.S.M. and A.D.). Discrepancies were resolved by consensus or, if necessary, by a third investigator (A.N.B.).
Data Abstraction and Validity Assessment
Data from included articles, including baseline characteristics, indication for and duration of NOAC, and number, severity, and location of GI bleeding events were compiled. Study investigators were contacted for specification of bleeding data regarding anatomic site (ie, GI tract), location (upper vs lower), and severity (major, minor, or clinically relevant nonmajor [CRNM] ) if these data were not reported. The Jadad score and Cochrane Risk Bias Tool were used to grade the quality of included studies and to assess potential bias, respectively.
Choice of Outcomes
The primary outcome of interest was the odds of major GI bleeding associated with NOACs compared with conventional anticoagulation therapy. Major bleeding was defined as per the International Society of Thrombosis and Haemostasis as a decrease in hemoglobin level of 2 g/dL or requiring 2 or more units of packed red blood cells. 6 Secondary outcomes included comparative odds of total, CRNM, minor, upper, and lower GI bleeding. CRNM bleeding generally was defined as overt bleeding not meeting the criteria for major bleeding but associated with medical intervention, unscheduled contact with a physician, temporary cessation of study treatment, or discomfort for the subject such as pain or impairment of activities of daily life. Minor bleeding was defined as overt bleeding not meeting the criteria for major or CRNM bleeding. A post hoc analysis assessing hazard ratios (HRs) also was performed to account for the duration of therapy. With the exception of subgroup analyses by comparator, specified outcomes were calculated combining data across all included studies, regardless of what agent was used as the control.
Sources of Potential Clinical and Statistical Heterogeneity
Comparative qualitative analyses were performed to assess the heterogeneity of patient populations, interventions, and outcomes across studies, guiding possible subgroup analyses. A priori subgroup analyses examined the difference in major GI bleeding among individual NOACs, indication for anticoagulation, and country of publication. Subgroup analysis by indication also served as a surrogate for the duration of therapy. Sensitivity analyses were performed for high study quality, more recent publication, and fully published trials. Post hoc subgroup analyses of the primary outcome according to comparator were performed, as were sensitivity analyses within individual NOAC subgroups, removing studies one at a time.
Statistical Methods and Sensitivity Analyses
For each outcome and in every comparison, effect size was calculated with odds ratios (ORs) for categoric variables. The Mantel-Haenszel method for fixed-effect models were applied to all comparisons to determine corresponding overall effect sizes and their confidence intervals (CIs). A random-effects model was used if statistical heterogeneity was noted, using the DerSimonian and Laird 7 method. The presence of heterogeneity across studies was defined using a chi-square test of homogeneity with a 0.10 significance level. 8 The Higgins I 2 statistic 9 was calculated to quantify the proportion of variation in treatment effects attributable to between-study heterogeneity. Values of 25%, 50%, and 75% represent low, moderate, and high heterogeneity, respectively. To identify possible sources of statistical heterogeneity, sensitivity analyses were performed, excluding studies one at a time. In addition, if at least 10 trials were selected for analysis, we planned to perform meta-regression using a mixedeffects model according to predefined relevant variables. 10 For all comparisons, publication bias was evaluated using the Begg adjusted rank correlation test 11 and the Egger regression asymmetry test. 12 Summary statistics were expressed as means and SD. To ensure that zero event trials did not significantly affect the heterogeneity or P value, a continuity correction was added to each trial with zero events using the reciprocal of the opposite treatment arm size. 13 All statistical analyses were performed using Meta package in R version 3.2.1 (R Foundation for Statistical Computing, Vienna, Austria, 2008).
Results
Included Studies
The initial search yielded 1940 citations ( Figure 1 ). After screening based on title and abstract, 1858 results were excluded and 82 articles were reviewed in full. Of these, 40 articles representing 43 trials were included, 4,14-52 randomizing 166,289 patients to receive NOACs dabigatran, rivaroxaban, apixaban, edoxaban, or betrixaban. Barring 1 abstract that did not specify, 51 all major bleeding was defined in accordance with the International Society of Thrombosis and Haemostasis. 6 Table 1 summarizes included studies. Inter-rater Heterogeneity, Study Quality, and Publication Bias
Inter-rater citation selection yielded a moderate level of agreement with a k value of 0.76 (0.72-0.80). The Jadad quality scores ranged from 0 to 4 of a maximum of 5 points, with a mean of 3.0 AE 1.2. Performance bias according to the Cochrane Risk Bias tool was noted in a few studies with an open-label methodology (Supplementary Figure 1) . Heterogeneity was noted for the primary outcome as well as studies published in North America, high study quality, recent publications, AF as an indication for therapy, and trials with warfarin as control ( Table 2) (129,357 patients) regarding odds of major GI bleeding using a random-effects model (1.5% vs 1.3%, respectively; OR, 0.98; 95% CI, 0.80-1.21) (Figure 2) . No difference was found for any of the secondary outcomes including total, CRNM, minor, upper, and lower GI bleeding (Table 2) .
Primary and Secondary Outcomes
Meta-analysis of HRs showed no difference in major GI bleeding risk between NOACs and conventional therapy, including 3 studies 4,19,32 (4 arms) assessing 44,765 patients (HR, 0.89; 95% CI, 0.66-1.22) (Supplementary Figure 2) . 
Subgroup and Sensitivity Analyses
0.78-1.11) (Figure 4). No difference in major GI
bleeding was observed between NOACs collectively and conventional therapy for any indication or vs any comparator. Subgroup analyses by region showed no difference among any group except Asian studies in which NOACs were associated with decreased odds of major GI bleeding (0.5% vs 1.2%, respectively; OR, 0.45; 95% CI, 0.22-0.91). Sensitivity analyses of primary outcome by high study quality, more recent publication, only fully published trials, and removing studies one at a time showed no difference in major GI bleeding risk ( Table 2, Supplementary Table 1) . Post hoc sensitivity analyses were performed on the subgroup analyses by individual NOAC. First, using a Table 1 ).
Meta-Regression Analysis
By using the mixed-effects model, a meta-regression was performed, identifying recent publications as inversely related to major GI bleeding (OR, -0.44; 95% CI, -0.74 to -0.14). North American (OR, 0.64; 95% CI, 0.01-1.29), and rivaroxaban publications (OR, 0.47; 95% CI, 0.21-0.73) were associated with increased major GI bleeding events.
Discussion
We identified 43 RCTs comparing NOACs with conventional anticoagulation, of which 28 (129,357 patients) provided data on GI bleeding. Our primary outcome showed no significant difference in major GI bleeding when NOACs were compared collectively with conventional anticoagulation. Prespecified subgroup analyses, however, showed increased odds of major GI bleeding associated with dabigatran and rivaroxaban, with 27% and 40% relative increases, respectively. No such difference was observed for factor Xa inhibitors apixaban or edoxaban. To further identify possible sources of heterogeneity within the primary outcome, an a priori meta-regression analysis identified 3 variables that accounted for the full measured between-study heterogeneity, including randomization to rivaroxaban, which was associated with an increased risk of GI bleeding.
Observational studies have shown variable risk of GI bleeding associated with NOACs. Population-based data in studies by Graham et al 53 and Hernandez et al 54 have found that among patients with AF, dabigatran was associated with an increased rate of GI bleeding relative to warfarin. The latter found a further augmented risk in patients with renal dysfunction and those of African American descent. 54 Abraham et al 55 reported no difference between rivaroxaban or dabigatran compared with warfarin, except in patients older than age 75, in which case both drugs were associated with an increased risk of GI bleeding. Other studies showed no increased risk associated with either of these 2 agents.
56-58 A recent propensity-matched cohort study in patients with AF found increased, equivalent, and decreased risks associated with rivaroxaban, dabigatran, and apixaban, respectively, compared with warfarin. 59 To further explore the observed NOAC-specific GI bleeding associations in the current analysis, post hoc analyses were performed. First, the a priori subgroup analyses showing increased risk associated with dabigatran and rivaroxaban were performed using a fixed-effects model because no significant statistical heterogeneity was present. Post hoc analyses were performed using the more conservative random-effects model, which showed no significant difference in odds of major GI bleeding compared with conventional therapy (dabigatran: OR, 1.25; 95% CI, 0.97-1.60; rivaroxaban: OR, 1.17; 95% CI, 0.63-2.18). Second, when the AF trials RELY and ROCKET AF were removed from the analyses, no increased risk was observed for dabigatran or rivaroxaban, respectively. Of note, these trials had the highest observed GI bleeding event rates within their respective NOAC subgroups, likely attributed to the longer durations of therapy and the larger sample sizes. Interestingly, apixaban was associated with significantly lower odds of major GI bleeding compared with conventional anticoagulation when excluding the ADVANCE-3 trial in a post hoc analysis. This is in keeping with recently published observational data, which found apixaban to be associated with a 49% relative risk reduction in GI bleeding relative to warfarin. 59 Taken together, the current data suggest possible variability across NOACs regarding GI bleeding risk, with a concern for increased risk associated with rivaroxaban and dabigatran. Conversely, the data do not suggest that apixaban or edoxaban are associated with increased risk. The biological basis for this potential difference in GI bleeding risk is not clear. Regarding dabigatran, it has been proposed that the tartaric acid coating has a direct caustic effect on the intestinal lumen. 60 It also has been observed that NOACs have some degree of intraluminal anticoagulant activity resulting from their incomplete absorption across the GI mucosa. This is in contrast to warfarin, which almost completely is absorbed, and parenteral anticoagulants, which are not administered orally. 60 Although this hypothesis may help explain an increased risk associated with dabigatran and rivaroxaban compared with conventional therapy, it does not account for the difference among NOACs. Independent from risk of GI bleeding, it is important to recognize that all 4 studied agents have been associated with a significantly reduced risk of intracranial bleed in their respective large AF trials. 4, 5 North American gastroenterology guidelines largely have not addressed the risk of NOAC-associated bleeding, or the potential for mitigating risk. There may be benefit in risk-stratifying patients requiring longterm anticoagulation by risk of GI bleeding. Impaired renal or hepatic function, advanced age, low body weight, and concomitant use of antiplatelet agents are reported to be associated with increased theoretical or observed risk of GI bleeding while taking dabigatran and rivaroxaban. 61 Creation and validation of a NOACspecific scoring tool that can estimate the long-term risk of GI bleeding may help clinicians tailor therapy to their patients. Until such a tool is created using highquality, population-based data, clinicians may choose to use existing scoring tools that estimate the risk of bleeding while on therapeutic anticoagulation, such as the HAS-BLED score. 62 Of note, this and other risk scores are not validated for estimating bleeding risk on NOACs. In patients at increased risk of GI bleeding, clinicians might opt for an agent with a safety profile that favors less GI bleeding. For patients who take a higher-risk NOAC and with recognized risk factors for upper GI bleeding, there may be benefit in prophylaxis with antiacid therapy. Indeed, a recent retrospective study from Hong Kong showed less upper GI bleeding among patients taking either H 2 -receptor antagonists or proton pump inhibitors with dabigatran. 63 Subgroup analysis by region showed that, for Asian studies, NOACs were associated with significantly decreased odds of major GI bleeding. Of note, these studies encompassed all indications and most NOACs and comparators. Although it has been shown that variations in the VKORC1 gene contribute to differences in warfarin sensitivity such that the Asian population is more likely than others to be warfarin-sensitive, 64 this is unlikely to account for the observed difference. First, studies administered dose-adjusted warfarin, so that even if lower doses were required for therapeutic effect this should not affect bleeding risk; and, second, this would apply only to the studies with warfarin as a comparator. Whether this finding can be explained by an inherent difference in patient population or in study design remains uncertain.
Our meta-analysis was limited by a lack of reported data. Fifteen of 43 studies (35%) failed to specify the source of bleeding events (eg, GI tract) and, ultimately, were excluded from our quantitative analysis. Furthermore, few studies reported GI bleeding events that were nonmajor in severity and few studies specified the location of the bleed within the GI tract. We could not account for patient-specific risk factors including use of concomitant medications that may have increased the risk of GI bleeding events. Although this limited our ability to characterize further the risk of GI bleeding while taking NOACs, we do not expect major bias a priori because risk factors generally are distributed evenly across treatment arms in large randomized controlled trials. Ultimately, patient-based data would be required to identify factors that predispose patients to GI bleeding events and to better characterize NOAC-associated GI bleeding. Regarding our study selection, we included only English and French studies in our analysis. After reviewing all abstracts we identified only 3 non-French, non-English RCTs, randomizing a total of 287 patients, which were excluded based on language alone. Four studies (3 articles) included in our primary analysis were classified as extension studies. 15, 34, 47 They were judged to fulfill the prespecified inclusion criteria because all patients were re-randomized and patients who experienced a bleeding event were excluded.
A previously published meta-analysis investigated the risk of GI bleeding associated with the NOACs, reporting an overall increased risk driven by treatment of acute coronary syndrome and VTE. 65 Our study updates the current evidence, showing potentially significant differences across NOACs. Furthermore, our article adds to this previously published work by focusing on studies investigating NOACs for approved indications. Finally, an important strength of our analysis was a rigorous statistical methodology accounting for clinical and statistical heterogeneity.
In conclusion, the NOACs as a whole appear to confer no increase in the odds of GI bleeding. The potentially increased risk of GI bleeding associated with dabigatran and rivaroxaban observed in some of our subgroup analyses merits further consideration. Future high-quality, observational studies are needed to confirm our findings and to provide additional insight into their clinical relevance. 
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